1,500 reports of this reaction
1.7% of all RIBOCICLIB reports
#12 most reported adverse reaction
BREAST CANCER METASTATIC is the #12 most commonly reported adverse reaction for RIBOCICLIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,500 FDA adverse event reports linking RIBOCICLIB to BREAST CANCER METASTATIC. This represents approximately 1.7% of all 86,238 adverse event reports for this drug.
RIBOCICLIB has an overall safety score of 85 out of 100. Patients taking RIBOCICLIB who experience breast cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER METASTATIC is a less commonly reported adverse event for RIBOCICLIB, but still significant enough to appear in the safety profile.
In addition to breast cancer metastatic, the following adverse reactions have been reported for RIBOCICLIB:
The following drugs have also been linked to breast cancer metastatic in FDA adverse event reports:
BREAST CANCER METASTATIC has been reported as an adverse event in 1,500 FDA reports for RIBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER METASTATIC accounts for approximately 1.7% of all adverse event reports for RIBOCICLIB, making it a notable side effect.
If you experience breast cancer metastatic while taking RIBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.